Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 2/20 | 0.37 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL893472 | 0.94 | GRM1 (0.37) | GRM1FFAR3CYP2C19SMN1; SMN2LMNA | |
| SCHEMBL10151921 | 0.91 | GRM1 (0.36) | GRM1FFAR3CYP2C19SMN1; SMN2LMNA | |
| SCHEMBL16933182 | 0.87 | GRM1 (0.40) | GRM1FFAR3CYP2C19 | |
| SCHEMBL17893428 | 0.84 | FFAR3 (0.38) | GRM1FFAR3CYP2C19AKR1C1 | |
| SCHEMBL10015844 | 0.82 | PKM (0.34) | GRM1CYP2C19PKML3MBTL1 | |
| SCHEMBL3213118 | 0.82 | NPSR1 (0.39) | FFAR3LMNAMEN1KMT2A | |
| SCHEMBL478303 | 0.80 | GRM1 (0.40) | GRM1FFAR3CYP2C19 | |
| SCHEMBL9142496 | 0.79 | GRM1 (0.50) | GRM1FFAR3LMNAPKML3MBTL1 | |
| SCHEMBL1648486 | 0.79 | GRM1 (0.50) | GRM1FFAR3LMNAPKML3MBTL1 | |
| SCHEMBL9506878 | 0.78 | CYP2C19 (0.40) | GRM1FFAR3CYP2C19SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1794120-B1 | PEPTIDASE INHIBITORS | NUADA LLC (US) | 2012-04-11 | — | — | EP | disclosed |
| US-7842707-B2 | Peptidase inhibitors | NUADA, LLC (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842707-B2 | Peptidase inhibitors | NUADA, LLC (US) | 2010-11-30 | — | — | US | disclosed |
| EP-2121626-A1 | BENZIMIDAZOLE DERIVATIVES | Pfizer Products Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080234292-A1 | Such as S)-(1-(1-Aminobicyclo[2.2.2]oct-4-yl)aminoacetyl)-2-cyanopyrrolidine; inhibitors of the enzyme dipeptidyl peptidase; antidiabetic agents | NUADA, LLC | 2008-09-25 | — | — | US | disclosed |
| US-20080234292-A1 | Such as S)-(1-(1-Aminobicyclo[2.2.2]oct-4-yl)aminoacetyl)-2-cyanopyrrolidine; inhibitors of the enzyme dipeptidyl peptidase; antidiabetic agents | NUADA, LLC | 2008-09-25 | — | — | US | disclosed |
| WO-2008075196-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234292-A1 | Such as S)-(1-(1-Aminobicyclo[2.2.2]oct-4-yl)aminoacetyl)-2-cyanopyrrolidine; inhibitors of the enzyme dipeptidyl peptidase; antidiabetic agents | DPP3, DPP4, DPP7 | GRM1 1369/4885FFAR3 467/4885CYP2C19 1518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.